At #DaiichiSankyoEurope, our aim is to support as many people living with cancer across Europe as possible. That is why we are very excited to announce a new affiliate for oncology in Athens, Greece! 💥 Establishing this presence in Greece is a continuation of Daiichi Sankyo’s deep-rooted commitment to serving the patient community, helping to improve their quality of life and address their unique needs 💚 We aim to actively contribute to the Greek healthcare ecosystem by partnering with the scientific community, governmental organisations and patient advocacy groups, and are fortunate to have a wealth of clinical expertise as well as a vibrant research community in Greece. Together with this new affiliate, we are excited to continue promoting innovation and advancement, working as one to improve the sustainability of cancer care and achieve excellence globally 🌍 #CancerCare #DSEGreece
Daiichi Sankyo Europe GmbH
Arzneimittelherstellung
Passion for Innovation. Compassion for Patients.
Info
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people around the world by leveraging our world-class science and technology. In Europe, we want to become the benchmark for customer centricity in the areas we work in and a competitive player in Oncology. For these reasons we are constantly looking for new talents that are willing to deliver the best solutions to the various healthcare professionals who aim to provide their patients with the best possible therapy - whether in the cardiovascular or oncological field. We know that our success in Europe relies on courageous people who seize opportunities and turn them into results. This is why we encourage our teams across Europe to be passionate about their objectives, challenge conventional thinking and share their local recipes for success and learnings with the whole company. It is only through their input, ideas and honest feedback that we can learn and leverage the full potential of our company. In Europe we are operating in 13 countries. Because of our rather small size compared to larger pharmaceutical companies, each of our employees can have a huge impact – whether they work in the medical area, sales force, business intelligence or the IT department. This is why everybody at Daiichi Sankyo rolls up their sleeves and gets things done, even if this means that they sometimes have to go beyond their usual duties. If you would like to be an active member of our European family, we highly appreciate your application. Please take a look at our current vacancies. Imprint: https://www.daiichi-sankyo.eu/imprint/ All information posted by Daiichi Sankyo Europe on this channel is intended for non-US, non-Canada & non-UK visitors.
- Website
-
http://www.daiichi-sankyo.eu
Externer Link zu Daiichi Sankyo Europe GmbH
- Branche
- Arzneimittelherstellung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Munich
- Art
- Einzelunternehmen (Gewerbe, Freiberufler etc.)
- Gegründet
- 1899
- Spezialgebiete
- cardiovascular diseases, glucose metabolic disorders, infectious diseases, cancer / oncology, immunity and allergies, and bones/joint diseases, antibody drug conjugates, anticoagulation und ADC
Orte
-
Primär
Zielstattstraße 48
Munich, 81379, DE
-
Zielstattstrasse 48
Munich, BY 81379, DE
Beschäftigte von Daiichi Sankyo Europe GmbH
Updates
-
What does #DevelopAndGrow mean to you in your professional environment❓ At #DaiichiSankyo in Europe, one of our core behaviours is to Develop and Grow – meaning, we encourage all our employees to learn, experiment, and take initiative, enabling them to grow every day in their role. Laura Martin, Senior Director Global Oncology, explains what this core behaviour means to her and why she values Daiichi Sankyo’s commitment to Develop and Grow – including how other aspects of the environment help with this, like the promotion of physical activities, well-being and healthy lifestyles. She also explains how the value supports us all to contribute to our common goal – improving the quality of life of patients around the world 👇 #DaiichiSankyoEurope #CoreBehaviours
-
Improving outcomes for all cancer patients is a mission that the Workgroup of European Cancer Patient Advocacy Networks (WECAN) and #DaiichiSankyoEurope have in common 💚 WECAN Academy works to strengthen cancer patient advocacy in Europe, as well as increase alignment and collaboration between European cancer patient organisations. Daiichi Sankyo Europe is proud to sponsor WECAN, ensuring it can continue to support people living with cancer across Europe. Visit WECAN’s website to find out more about their initiatives 👉 https://ow.ly/gLXT50Sp6TZ
-
Daiichi Sankyo has been named one of the #LinkedInTopCompanies 2024! 🏆 We are proud to be recognized as one of the top 25 employers in Germany in the large companies category. 🥳 LinkedIn assessed key factors such as career advancement opportunities, skill development, internal career prospects, and gender diversity to determine this ranking. This is a great recognition of our commitment to fostering our employees and offering them exciting opportunities in the pharmaceutical industry. A big thank you to everyone who has made this possible! 👏🏻
-
-
📣We’re hiring for three positions across Europe and Germany 📣 At #DaiichiSankyo in Europe, we are a diverse team who are committed to making a positive impact in health. Discover some of the available positions by following the links below! 💚 Director, Global R&D Business Application Training & OCM Lead 👉 https://lnkd.in/dRexP4em 💚 Customer Experience Senior Manager, Cardiovascular 👉 https://lnkd.in/dTR5XBkS 💚 Global Oncology HEOR & Payer Evidence Generation, Senior Manager 👉 https://lnkd.in/d94jUGGP #UnlockYourPotential #DaiichiSankyoCareers
-
During the European Week Against Cancer earlier this year, GAMIAN-Europe and Cancer Patient Europe launched a mental-health toolkit designed to support the mental wellbeing of people living with cancer 💡 A cancer diagnosis and treatment can often have a significant impact on someone’s mental wellbeing, and the risk of developing depression is significantly heightened in people living with cancer. The toolkit is an interactive guide designed to help readers navigate the dual challenges of cancer and depression 🎗️💪 Read more on how to manage mental wellbeing in the toolkit here 👉 https://ow.ly/XGET50SpbTC #MentalHealthAwareness #EWAC2024 #CancerSupport
-
We are back with our Pharma Jobs Explained series, where we explore various roles at #DaiichiSankyo 🤗 One area you might not be familiar with is ‘Market Access and Pricing’. This role is crucial in driving our mission and vision forward as it ensures that products are available to those who need them most. It also involves determining their value and setting prices that reflect this. Dr. Maximilian Hatz, Senior Director of European Market Access & Pricing in Oncology at #DaiichiSankyoEurope, shared his day-to-day responsibilities in his role. Read below to find out what he gets up to 👇 #IndustryExplained #RolesInPharma
-
At #DaiichiSankyo, our employees are the driving force behind our success, and we value every person’s unique contribution. We are committed to providing a diverse range of experiences for our employees, and ensuring their career is full of valuable opportunities. Felix Kahnwald’s journey started in 2019 in the German affiliate as Marketing Lead for Oncology, from which he transitioned to the Director for Breast Cancer in the European Team in 2020. Following this he has transitioned back to Daiichi Sankyo Deutschland GmbH, where he now works as a First Line Sales Manager – an extremely important role for our organisation. During his career, Felix has had to rise to new challenges which has allowed him to build a wider set of skills and ultimately lead a team who values mutual trust and honest communication. Learn more from Felix on his advice on how to approach challenges, and how working at Daiichi Sankyo has shaped his career 👇 #OurPeople
-
Recently Daiichi Sankyo España held its second edition of #MetacardioDS, a sustainable innovation event where they looked at the future of #CardiovascularHealth. The aim of the event was to help professionals understand how new technologies and #ArtificialIntelligence (AI) are going to change the cardiovascular diagnosis landscape. AI is set to revolutionise cardiology in the next decade, from optimising diagnostics to individualised care. In addition, studies based on cardiac interventions using virtual reality (VR) have grown significantly. During the event, the team presented the #DoctopediaXR platform, an extended reality training platform that will help healthcare professionals gain practical skills in a safe and controlled environment. Studies show that adopting new technologies, especially VR, include numerous benefits and improve the efficiency of medical trainings3 and we are proud of #DaiichiSankyoES team’s commitment to innovation. #DaiichiSankyoEurope
-
Eating a healthy diet has many health benefits, including helping to reduce the risk of developing #CardiovascularDisease. In a recent interview with Joost Wesseling, Executive Director at The European Nutrition for Health Alliance, he explains why it is so important to approach #HeartHealth with connected stakeholders and healthcare professionals. At #DaiichiSankyoEurope we believe that implementing a #HolisticHealth approach to #CardiovascularHealth is crucial, and it is something we are committed to raising awareness of. Read more about the importance of nutrition in #CVD care here 👉 https://lnkd.in/eR-ZQqtk